Christopher Waddick
Direttore Finanziario/CFO presso CARDIOL THERAPEUTICS INC.
Patrimonio netto: 222 200 $ in data 30/06/2024
Profilo
Christopher J.
Waddick is currently the Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022.
He is also the President & Chief Financial Officer at Active Energy, Inc. since 2013 and the President at Nrj Consulting, Inc. since 2009.
Previously, he served as the Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Mr. Waddick holds an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 29/02/2024 | 110 000 ( 0.16% ) | 222 200 $ | 30/06/2024 |
Posizioni attive di Christopher Waddick
| Società | Posizione | Inizio |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Direttore Finanziario/CFO | 16/08/2018 |
Active Energy, Inc.
 Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Direttore Finanziario/CFO | 01/01/2013 |
| Nrj Consulting, Inc. | Presidente | 01/11/2009 |
Precedenti posizioni note di Christopher Waddick
| Società | Posizione | Fine |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Amministratore Delegato | - |
Formazione di Christopher Waddick
| York University | Masters Business Admin |
| Wilfrid Laurier University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
| Nrj Consulting, Inc. |
- Borsa valori
- Insiders
- Christopher Waddick
